Key result
Two doses of the RIX4414 rotavirus vaccine demonstrated 77.7% efficacy (95% CI 40.2-91.7%) against hospitalization for gastroenteritis among Indigenous children in Central Australia.
Why the study?
Does the RIX4414 rotavirus vaccine prevent hospitalization for gastroenteritis in Indigenous children?
Case-Control
Does the RIX4414 rotavirus vaccine prevent hospitalization for gastroenteritis in Indigenous children?
Effect estimate: Vaccine efficacy 77.7% (95% CI 40.2%-91.7%)
The monovalent rotavirus vaccine is highly effective against hospitalization for gastroenteritis and confirmed rotavirus infection in Indigenous children in a high-burden setting.
Supports rotavirus vaccination in high-burden Indigenous settings; extends case-control data but leaves open need for RCTs.
Indigenous children living in arid Central Australia experience frequent outbreaks of rotavirus gastroenteritis. A widespread outbreak of G9 rotavirus infection occurred several months after introduction of the RIX4414 rotavirus vaccine. We performed a retrospective case-control study to determine vaccine efficacy during the outbreak. Two doses provided an estimated vaccine efficacy of 77.7% (95% confidence interval, 40.2%-91.7%) against hospitalization for gastroenteritis. Vaccine efficacy was 84.5% (95% confidence interval, 23.4%-96.9%) against confirmed cases of rotavirus infection. Vaccination was effective in this high-burden setting.
No takes yet. Share an insight, caveat, or question.
Snelling et al. (2009) conducted a case-control in Rotavirus gastroenteritis. RIX4414 rotavirus vaccine vs. Unvaccinated was evaluated on Hospitalization for gastroenteritis (Vaccine efficacy 77.7%, 95% CI 40.2%-91.7%). Two doses of the RIX4414 rotavirus vaccine demonstrated 77.7% efficacy (95% CI 40.2-91.7%) against hospitalization for gastroenteritis among Indigenous children in Central Australia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: